Pharming Group missed Q2 2026 consensus revenue estimates and shares dropped 22% in a single session. Levi & Korsinsky is investigating potential securities law violations on behalf of PHAR investors who...
On May 7, 2026, Pharming Group's CEO reaffirmed full-year revenue guidance of $405 million to $425 million. Twelve weeks later, the Company cut that range to $375 million to $395 million and the stock...
Pharming Group's legacy product RUCONEST posted a 10% year-over-year sales decline in Q2 2026 -- and PHAR shares fell 22% the day it was reported. Levi & Korsinsky is investigating potential securities...
Pharming Group (NASDAQ:PHAR) executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company’s planned...
NEW YORK , Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR). Such investors are advised...
NEW YORK , Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR). Such investors are advised...
NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR). Such investors are advised...
NEW YORK , Feb. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR). Such investors are advised...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...
Shares of Outlook Therapeutics OTLK tumbled 54.1% after the FDA issued a second complete response letter (CRL) rejecting its biologics license application (BLA) resubmission for ONS-5010 in wet age-related...